Loncipoetin alfa (NuPIAO) vs NNG-DEPO

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Kidney Disease

Shared mechanism: Erythropoietin receptor (EPO-R) · full Chronic Kidney Disease pipeline

Loncipoetin alfa (NuPIAO)

Marketed by Shenyang Sunshine Pharmaceutical

Phase 3 in Chronic Kidney Diseasebiologic
Partial signal

NCT05211167 · Phase 3 · status unknown

This is a randomized, active-controlled Phase 3 trial with an adequately sized enrollment comparing the study drug against a standard recombinant erythropoietin, using change in hemoglobin, the measure that defines the anemia being treated, as its primary endpoint. However, the trial was not blinded, and results have not been posted yet. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)

Reported efficacy

hemoglobin concentration (25th-32nd week): Reached its pre-set primary endpoint (3SBio 2023 annual report; trial completed January 2024); no figures were given. (met)

Result source: NCT05211167

NNG-DEPO · Stimus

Developed by Nanogen Pharmaceutical Biotechnology

Phase 3 in Chronic Kidney Diseasebiologic (registry-typed, subtype undisclosed)
Partial signal

NCT05585645 · Phase 3 · completed

The trial was randomized, double-blind, and actively controlled with Aranesp, enrolling 214 participants. However, its primary endpoint was a hemoglobin change measure rather than a hard clinical outcome, and no primary comparison results are available.

No aligned efficacy figure on record for this race.

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLoncipoetin alfa (NuPIAO)NNG-DEPO
Kidney composite outcome—Not reported—Not posted · NCT05585645
UACR, % change—Not reported—Not posted · NCT05585645
eGFR slope—Not reported—Not posted · NCT05585645
Haemoglobin, change—Not reported—Not posted · NCT05585645

Kidney composite outcome

Loncipoetin alfa (NuPIAO)
—Not reported
NNG-DEPO
—Not posted · NCT05585645

UACR, % change

Loncipoetin alfa (NuPIAO)
—Not reported
NNG-DEPO
—Not posted · NCT05585645

eGFR slope

Loncipoetin alfa (NuPIAO)
—Not reported
NNG-DEPO
—Not posted · NCT05585645

Haemoglobin, change

Loncipoetin alfa (NuPIAO)
—Not reported
NNG-DEPO
—Not posted · NCT05585645
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

NNG-DEPO: no structured comparison results are available for Chronic Kidney Disease.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Loncipoetin alfa (NuPIAO)
Reached its pre-set primary endpoint (3SBio 2023 annual report; trial completed January 2024); no figures were given. NCT05211167 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Loncipoetin alfa (NuPIAO)'s landscape · NNG-DEPO's landscape